FDA permits qualified health claim about whole grains and type 2 diabetes, but is the wording so qualified no one will use it?

Attorney: 'The FDA continues to engage in value laden qualification of claims in disregard of First Amendment limits on its power'

The FDA says it will permit qualified health claims on the relationship between eating whole grains and a reduced risk of type 2 diabetes, but is the wording it has proposed so qualified that no food manufacturer will want to use it?

Qualified health claims enable firms to talk about a relationship between a substance and disease where the supporting science fails to meet the FDA’s ‘significant scientific agreement’ standard, but the claims are ‘qualified’ in such a way as to not mislead consumers.

While the qualification often comes in the form of a far-from-consumer-friendly disclaimer, many observers believe the claims are still better than nothing.

The FDA has concluded that there is very limited scientific evidence for this claim

In a letter (click here) to ConAgra Foods responding to a petition it filed in early 2012, the FDA concluded: “The evidence supporting a risk reduction relationship, while credible, falls near the lower end of the ‘limited’ category and should be described as ‘very limited’ in food labeling to avoid misleading consumers.”

As a result, the FDA will consider exercising its enforcement discretion for the following qualified health claims:

'Whole grains may reduce the risk of type 2 diabetes, although the FDA has concluded that there is very limited scientific evidence for this claim.' 

OR: 'Whole grains may reduce the risk of type 2 diabetes. FDA has concluded that there is very limited scientific evidence for this claim.'

In its petition, ConAgra had suggested the following wording: 'Scientific evidence suggests, but does not prove, that diets low in saturated fat and cholesterol that include three servings (48g) of whole grains per day may reduce the risk of diabetes mellitus type 2.'

ConAgra: We’re disappointed with way FDA rated science, but this is a landmark

Jonathan Emord: Less value-laden terminology such as, 'The scientific evidence in support of this claim is inconclusive' would be preferable

ConAgra is “disappointed” with the way the FDA rated the science supporting its application, given that the Mayo Clinic and the National Institutes of Health - among others - had viewed it very differently, Mark Andon, Ph.D., Vice President of Nutrition at ConAgra Foods, told FoodNavigator-USA.

But on the plus side, he said, the first thing consumers will read if firms use these claims on food labels is: 'Whole grains may reduce the risk of type 2 diabetes’.

“In other qualified claims, the bit about how ‘limited’ the evidence is comes at the beginning, so I took this as a good sign", said Dr Andon.

"I’d hoped for more, but this is a landmark in the health claims area [with the exception of a highly-qualified claim about chromium picolinate and insulin resistance there are no other diabetes-related claims permitted on foods]. Many qualified health claims petitions are outright denied."

Asked whether ConAgra intended to go back to the FDA and try to convince it to re-word the claims, he said: “We have no intention of re-submitting the petition.”

So will ConAgra use the claims on pack?

Time will tell if we do”, said Dr Andon. “But being able to make them opens up an avenue so that what consumers see on pack is consistent with the messaging they are already getting from public health agencies and health care providers about whole grains and diabetes. Currently, they are hearing about this but it's not being reinforced when they go to the grocery store."

'The conditions of use are a little vague'

ConAgra Foods: “We were the originator of this petition and we’re thrilled the FDA is confirming that whole grains have a positive effect on people’s health and well-being and can help reduce the risk of developing type 2 diabetes"

As for the conditions of use, as with any health claim, the whole grain/diabetes claims are only permitted on foods below set thresholds for total fat, saturated fat, cholesterol and sodium, and containing at least 10% of the daily value of one or more of six key nutrients (vit A, vit C, calcium, iron, protein, fiber).

However, the FDA does not specify a minimum level of whole grains as a qualification for making the claim but says it will “look at the whole grain content of the food and monitor for any misleading use of the claim”.

This is "a little vague" admitted Dr Andon. However, in follow-up conversations with the FDA, he had been advised that as a benchmark for determining whether a food might qualify to make the claims, firms should look at the amounts of whole grains that "authoritative bodies have previously determined as not insignificant".

Thus a good starting point might be the 2010 Dietary Guidelines for Americans, which advise consumers to look for products with at least 8g of wholegrains per serving, he said.

Attorney: FDA continues to engage in value laden qualification of claims in disregard of First Amendment limits on its powers

So what do lawyers think of the FDA’s enforcement discretion letter?

FDA: 'Whole grains may reduce the risk of type 2 diabetes, although the FDA has concluded that there is very limited scientific evidence for this claim'

Leading food law attorney and qualified health claims expert Jonathan Emord was not impressed.

He told FoodNavigator-USA: “The FDA continues to engage in value laden qualification of claims in disregard of First Amendment limits on agency power. 

“Rather than compel ConAgra to communicate FDA’s perception of the relative value of science supporting the claim (ie. ‘There is very limited scientific evidence for this claim’), which violates the First Amendment, the FDA should have included the non-value laden qualification specified in Pearson v. Shalala: “The scientific evidence in support of this claim is inconclusive.” 

He added: “The process by which FDA comes to its conclusion of ‘very limited scientific evidence’ involves subjectively assigning weight to each piece of supportive evidence,  categorically rejecting some, to come to its conclusion of ‘very limited science’. 

“That process is imbued with bias ultimately expressed in a value laden qualification.  It thus offends First Amendment limits on the exercise of government discretion over speech.”

'Virtually all, if not all qualified health claims are phrased like this'

Marc Ullman, partner at law firm Ullman, Shapiro & Ullman, said that to him, the qualification of the permitted claims rendered them of "no utility".

However, the fact the FDA had even acknowledged a relationship between whole grains and type 2 diabetes was a step forward, he said, and some manufacturers might feel that the claim had some value.

Meanwhile, the PR generated around the 'approval' has been positive (the ConAgra press release does not refer to the wording of the actual claim), he said. 

Given that "virtually all, if not all" qualified health claims are phrased in this consumer-unfriendly manner, ConAgra had probably expected it would not get the wording it asked for, he said.

Whole Grains Council: It's too bad the claim is so watered down

Cynthia Harriman: We would be surprised to see companies rushing to add this statement to their packaging

Cynthia Harriman, director of food and nutrition strategies at the Whole Grains Council and Oldways, said she would be "surprised to see companies rushing to add this statement to their packaging".

She added: "We don't expect to see the use of statements like, 'May be just a little bit lower in calories' or 'probably tastes okay, but we're not sure.' Marketing just doesn't work that way.

"It's too bad the claim is so watered down, because of course we think diabetics would be better off eating whole grains."

General Mills did not say whether it would use the claim on its products, but said it was "pleased to see the FDA acknowledge the relationship between whole grain consumption and the reduced risk of Type 2 Diabetes".

A spokesperson added: "We are also pleased to see FDA reaffirm the widely accepted definition for whole grain as ‘consisting of the intact, ground, cracked or flaked caryopsis, whose principal anatomical components – the starchy endosperm, germ and bran – are present in the same relative proportions as they exist in the intact caryopsis'."

Click here to read ConAgra’s original petition of January 2012. 

Click here to read the FDA’s September 2013 response in full. 

Related News

Jaime Schwartz: 'For those diagnosed with prediabetes, the first line of defense in preventing diabetes is to lose weight, not to eat specially formulated products'

How can the food industry address the ticking time bomb of type 2 diabetes?

Dan Best: 'It is in the public interest to promote consumption of whole seeds…all whole seeds… versus refined or otherwise fractionated seeds'

Should the definition of ‘whole grains’ be expanded to include whole seeds, beans and legumes?

Dr Kaufman: "Fruit juice is really one of the worst things... You might as well drink Coca-Cola"

Diabetes expert: 'Juices are the worst, you might as well drink Coke...'

A pan-European whole grain labeling definition would need several categories and descriptions, says Jan-Willem van der Kamp from TNO Food and Nutrition

EU whole grain label laws could take over a year to define, says expert

Punching holes in pop-science theory: Whole grains may cut inflammatory biomarkers in obese kids

Punching holes in pop-science theory: Whole grains may cut inflammatory biomarkers in obese kids

ConAgra to FDA: There is ‘ample evidence’ to support qualified health claim on whole grains and type II diabetes

ConAgra to FDA: There is ‘ample evidence’ to support qualified health claim on whole grains and type II diabetes

If current trends continue, says the American Diabetes Association, one in three American adults will have diabetes by 2050

'Cobiotic' delivers dramatic decrease in fasting blood glucose and 'virtually eliminates' diarrhea caused by Metformin in type 2 diabetic: Case study

Boulder Brands CEO Steve Hughes: 'Diabetes is one of the largest and fastest growing need states in consumer foods today. However, it is an under-served market'

Boulder Brands buys Level Life Foods: ‘Diabetes is one of the fastest growing need states in consumer foods today’

Boulder Brands CEO Steve Hughes: “Diabetes is one of the largest and fastest growing need states in consumer foods today."

Tackling the diabetes epidemic: Blood glucose management a ‘significant untapped market’, says Frost & Sullivan

Comments (4)

Marco Aurilio - 27 Sep 2013 | 11:10

the FDA is part of the diabetic problem

Unfortunately the FDA's nutritional guidelines contribute to the diabetic growth and healthcare burden we see today. On Nutrition facts they include dietary fiber as part of total carbohydrates. They have no high sugar warnings.Their campaign to promote Low fat diets actually contributes to the development of diabetes and metabolic syndrome. They allow nutritionally bankrupt foods to appear healthy. Whole grains are healthier than refined, bleached flour, however in their usual fashion the FDA is doing too little too late. I will whole heartedly agree with Marc Ullman here and concur that these new qualified health claims are of "NO UTILITY"

jane margolis - 26 Sep 2013 | 09:25

qualified health claims misleading

If there is a connection between consuming whole grains and the incidence reduction of diabetes, that information can be found through public health authorities NOT from food labels. The only reason food manufacturers want to use qualified health claims is to sell their products, not to inform the consumer. In fact, they are just tricking the consumer and this is the reason the FDA resists these type of claims. They are a government watchdog for the consumer not the food industry. It is my opinion that health claims and structure function claims should not be permitted at all. Only nutrient content claims are useful to the consumer when comparing the nutrient content of foods.

MORE COMMENTS

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.